MOL #42382 1 Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells
نویسندگان
چکیده
Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands: EG, CL, CT, KS, JAR, GJP; Division of Pharmacology and Chemotherapy, Department of Internal Medicine, University of Pisa; Italy: EG, SN, SR, RD; Medical Oncology Branch, National Cancer Institute, Bethesda, MD, US: GG Molecular Pharmacology Fast Forward. Published on January 10, 2008 as doi:10.1124/mol.107.042382
منابع مشابه
Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
Because the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib and the multitargeted antifolate pemetrexed are registered in the treatment of second-line non-small-cell lung cancer (NSCLC), empirical combinations of these drugs are being tested. This study investigated molecular mechanisms underlying their combination in six NSCLC cell lines. Cells were characterized by...
متن کاملMolecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells
Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands: EG, CL, CT, KS, JAR, GJP; Division of Pharmacology and Chemotherapy, Department of Internal Medicine, University of Pisa; Italy: EG, SN, SR, RD; Medical Oncology Branch, National Cancer Institute, Bethesda, MD, US: GG Molecular Pharmacology Fast Forward. Published on January 10, 2008 as doi:10.1124/mol.107...
متن کاملSchedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells.
PURPOSE This study was undertaken to select the optimal combination schedule of erlotinib and pemetrexed for the treatment of relapsed non-small cell lung cancer (NSCLC) using a panel of human NSCLC lines. EXPERIMENTAL DESIGN Human NSCLC cell lines, with variable expression of the known molecular determinants of erlotinib sensitivity, were exposed to pemetrexed and erlotinib using different s...
متن کامل2D-QSAR and docking studies of 4-anilinoquinazoline derivatives as epidermal growth factor receptor tyrosine kinase inhibitors
Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor derivatives play an important role in the treatment of cancer. We aim to construct 2D-QSAR models using various chemometrics using 4-anilinoquinazoline-containing EGFR TKIs. In addition, the binding profile of these compounds was evaluated using a docking study. Materials and Methods: In this study, 122 compounds of...
متن کاملDose erlotinib add beneficial effect on cytotoxic agent for patients with pretreated advanced non-small cell lung cancer?
Combination of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) with platinumcontaining standard chemotherapy failed to provide better outcomes in the first-line setting for advanced nonsmall cell lung cancer (NSCLC) in several phase III trials. The approved monotherapy of erlotinib, pemetrexed or docetaxel as the second-line regimen still remains unsatisfactory in anti-tum...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2008